Ranibizumab · intravitreal implant
Injections & Implants
Neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor.
Contraindications
- Ocular or periocular infections
- Active intraocular inflammation
- Known hypersensitivity to ranibizumab products or any of the excipients in SUSVIMO
100 mg/mL (10 mg/0.1 mL) single-dose vial, alone or in a kit with an initial fill needle; initial fill needle; refill needle
Ranibizumab binds to the receptor binding site of multiple biologically active forms of VEGF-A, including VEGF 110. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
For intravitreal use via the SUSVIMO ocular implant. The recommended dose is 2 mg (0.02 mL of 100 mg/mL solution) continuously delivered via the implant, with refills every 24 weeks in neovascular AMD and diabetic macular edema, and every 36 weeks in diabetic retinopathy. Supplemental treatment with 0.5 mg intravitreal ranibizumab injection may be administered in the affected eye while the SUSVIMO implant is in place and if clinically necessary. The initial fill, implant insertion and implant removal procedures must be performed under aseptic conditions by a physician experienced in vitreoretinal surgery. Do not administer as a bolus intravitreal injection, and do not substitute other ranibizumab products.
Warnings & Precautions
- Endophthalmitis: the SUSVIMO implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab (1.7% vs 0.5% in the active comparator period of controlled clinical trials in AMD). Many, but not all, of the cases reported a preceding or concurrent conjunctival retraction or erosion event. Endophthalmitis should be treated promptly, and the dose (refill-exchange) should be delayed until resolution of endophthalmitis.
- Rhegmatogenous retinal detachment: rhegmatogenous retinal detachments have occurred in clinical trials of SUSVIMO and may result in vision loss. They should be promptly treated, and the dose (refill-exchange) should be delayed in the presence of a retinal detachment or retinal break. Suspected areas of abnormal vitreo-retinal adhesion or retinal breaks should be treated before inserting the implant in the eye.
- Implant dislocation: in clinical trials, the device has dislocated/subluxated into the vitreous cavity or has extended outside the vitreous cavity into or beyond the subconjunctival space. Device dislocation requires urgent surgical intervention.
- Septum dislodgement: in clinical trials, a type of implant damage where the septum has dislodged into the implant body has been reported. Perform a dilated slit lamp exam and/or dilated indirect ophthalmoscopy prior to and after the refill-exchange procedure to identify septum dislodgement. Discontinue treatment with SUSVIMO following septum dislodgement and consider implant removal should the benefit of the removal procedure outweigh the risk.
- Vitreous hemorrhage: vitreous hemorrhages may result in temporary vision loss, and vitrectomy may be needed in the case of a non-clearing vitreous hemorrhage. Temporarily discontinue antithrombotic medication prior to the implant insertion procedure to reduce the risk of vitreous hemorrhage. The dose (refill-exchange) should be delayed in the event of sight-threatening vitreous hemorrhage.
- Conjunctival erosion, retraction or bleb: conjunctival erosions or retractions have been associated with an increased risk of endophthalmitis, especially if the implant becomes exposed, and surgical intervention (e.g., conjunctival/Tenon's capsule repair) is recommended. Conjunctival blebs may require surgical management. The implant and the tissue overlying the implant flange should be monitored routinely following the implant insertion and refill-exchange procedures.
- Postoperative decrease in visual acuity: a decrease in visual acuity usually occurs over the first two postoperative months.
- Postoperative intraocular inflammation: postoperative intraocular inflammation has occurred following SUSVIMO implantation. The majority of cases occurred during the first week following implantation and resolved within the first month.
- Air bubbles causing improper filling of the implant: air bubbles within the implant reservoir may cause slower drug release. During the initial fill procedure, if an air bubble is present, it must be no larger than 1/3 of the widest diameter of the implant, and if excess air is observed after initial fill, do not use the implant. If excess air bubbles are observed after the refill-exchange procedure, consider repeating the refill-exchange procedure.
- Deflection or movement of the implant: use caution when performing ophthalmic procedures (e.g., B-scan ophthalmic ultrasound, scleral depression, or gonioscopy) that may cause deflection or movement of the implant and subsequent injury.
Common Side Effects
In AMD, the most common (≥ 10%) adverse reactions up to Week 40 were conjunctival hemorrhage (72%), conjunctival hyperemia (26%), iritis (23%), and eye pain (10%). In DME, the most common (≥ 10%) adverse reactions up to Week 64 were conjunctival hemorrhage (62%), conjunctival hyperemia (15%), iritis (14%), eye pain (13%), cataract (11%), conjunctival disorder (10%) and vitreous hemorrhage (10%). In DR, the most common (≥ 10%) adverse reactions up to Week 52 were conjunctival hemorrhage (73%), conjunctival disorder (14%), iritis (12%) and conjunctival hyperemia (11%).
Pregnancy: There are no adequate and well-controlled studies of SUSVIMO administration in pregnant women. Administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses up to 41 times the human exposure, and based on the anti-VEGF mechanism of action treatment may pose a risk to human embryofetal development.
Lactation: There are no data available on the presence of ranibizumab in human milk, the effects of ranibizumab on the breastfed infant or the effects of ranibizumab on milk production. Caution should be exercised when SUSVIMO is administered to a nursing woman.
The safety and efficacy of SUSVIMO in pediatric patients have not been established.